Dr. Gabriel Scally:

I completely understand. It is a difficult issue. Another difference, and Dr. Denton will keep me right on this, is that here a slide is examined twice. One is a primary screen, which is for a longer period than the secondary screen. That is the norm in the UK and Ireland. In the United States, the labs do not do secondary screens. The Irish women's slides which went to the United States had two primary level screens which involved the cytoscreener examining the slide for a longer period. In theory, it might be postulated, they should have fewer false negatives because they have more intensive screening, but it means that the data are not easily comparable with anywhere else. Those are the sorts of complications that make comparability really difficult.